Among U.S. adults 50+, lifetime psilocybin use was lower in cancer survivors from 2015–2019, at 6.4% versus 7.7% in people without cancer. Any classic psychedelic use reached 11.6% among cancer survivors, while cannabis use was nearly the same between groups at 41.6% versus 42.6%. Use varied by cancer type, with head and neck, cervical, and hepatobiliary/pancreatic cancer survivors showing the highest cannabis-and-psychedelic co-use, making this a strong real-world snapshot for aging, cancer care, and psychedelic literacy.